Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2

Phase 3

• Conditions: HIV Infections; Hepatitis A; Hepatitis B

• Registration Number: NCT00451984
• Lead Sponsor: Aalborg University Hospital

Brief Summary

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-03-23
• Study First Submitted QC: 2007-03-23
• Study First Posted: 2007-03-26
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-31
• Last Update Posted: 2007-11-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria

• Prior hepatitis A or B

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Antibody response to hepatitis A and hepatitis B

Trial Locations

Locations (2)

Department of Infectious Diseases, Skejby Hospital; 🇩🇰 Aarhus, Denmark

Department of Infectious Diseases, Aalborg Hospital; 🇩🇰 Aalborg, Denmark